JP5656406B2 - 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ - Google Patents

治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ Download PDF

Info

Publication number
JP5656406B2
JP5656406B2 JP2009538639A JP2009538639A JP5656406B2 JP 5656406 B2 JP5656406 B2 JP 5656406B2 JP 2009538639 A JP2009538639 A JP 2009538639A JP 2009538639 A JP2009538639 A JP 2009538639A JP 5656406 B2 JP5656406 B2 JP 5656406B2
Authority
JP
Japan
Prior art keywords
her3
receptor
antibody
tumor
phosphorylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009538639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510784A (ja
JP2010510784A5 (https=
Inventor
ローテ マイク
ローテ マイク
トレーダー マルティン
トレーダー マルティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Europe GmbH
Original Assignee
U3 Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38961070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5656406(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by U3 Pharma GmbH filed Critical U3 Pharma GmbH
Publication of JP2010510784A publication Critical patent/JP2010510784A/ja
Publication of JP2010510784A5 publication Critical patent/JP2010510784A5/ja
Application granted granted Critical
Publication of JP5656406B2 publication Critical patent/JP5656406B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
JP2009538639A 2006-11-28 2007-11-28 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ Active JP5656406B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86124306P 2006-11-28 2006-11-28
US60/861,243 2006-11-28
EP06024658 2006-11-28
EP06024658.4 2006-11-28
PCT/EP2007/010335 WO2008064884A1 (en) 2006-11-28 2007-11-28 Activated her3 as a marker for predicting therapeutic efficacy

Publications (3)

Publication Number Publication Date
JP2010510784A JP2010510784A (ja) 2010-04-08
JP2010510784A5 JP2010510784A5 (https=) 2011-01-20
JP5656406B2 true JP5656406B2 (ja) 2015-01-21

Family

ID=38961070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538639A Active JP5656406B2 (ja) 2006-11-28 2007-11-28 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３

Country Status (6)

Country Link
US (2) US20100047829A1 (https=)
EP (2) EP2097754B2 (https=)
JP (1) JP5656406B2 (https=)
AU (1) AU2007324868B2 (https=)
CA (1) CA2670522C (https=)
WO (1) WO2008064884A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
UA104868C2 (uk) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
US8652787B2 (en) 2008-11-12 2014-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ERBB4 as a prognostic and therapeutic marker for melanoma
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
US20120270745A1 (en) * 2009-07-15 2012-10-25 Prometheus Laboratories Inc. Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
CA2792327C (en) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
US20110318336A1 (en) * 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors
EP2590654B1 (en) 2010-07-09 2016-12-21 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
ES2670651T3 (es) * 2011-10-04 2018-05-31 Expression Pathology, Inc. Ensayo de SRM/MRM para determinar la proteína ERBB-4 del receptor de tirosina-proteína quinasa (HER4)
JP6180425B2 (ja) 2011-11-23 2017-08-23 メディミューン，エルエルシー Ｈｅｒ３に特異的な結合分子及びそれらの使用
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
KR101524915B1 (ko) 2013-05-10 2015-06-02 포항공과대학교 산학협력단 타이로신 인산화효소를 감지하는 형광 프로브 및 이의 용도
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
IL126303A (en) 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
CA2432276A1 (en) * 2000-12-22 2002-08-01 Dana-Farber Cancer Institute, Inc. Regulation of cell growth by muc1
US7125680B2 (en) * 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
KR20050037510A (ko) * 2002-06-05 2005-04-22 세다르스-신나이 메디칼 센터 키나제 억제제를 사용하는 암 치료 방법
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
CA2521077A1 (en) 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
JP4724657B2 (ja) * 2003-05-30 2011-07-13 アストラゼネカ ユーケー リミテッド プロセス
JP2005024385A (ja) 2003-07-02 2005-01-27 Matsushita Electric Ind Co Ltd 感圧センサ
US20060204966A1 (en) * 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
WO2005117553A2 (en) * 2004-05-27 2005-12-15 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos

Also Published As

Publication number Publication date
JP2010510784A (ja) 2010-04-08
US20160161491A1 (en) 2016-06-09
EP2097754B2 (en) 2018-01-24
CA2670522C (en) 2018-08-07
CA2670522A1 (en) 2008-06-05
AU2007324868B2 (en) 2014-03-20
EP2518508A1 (en) 2012-10-31
AU2007324868A1 (en) 2008-06-05
EP2097754A1 (en) 2009-09-09
US10365283B2 (en) 2019-07-30
EP2097754B1 (en) 2015-01-07
WO2008064884A1 (en) 2008-06-05
US20100047829A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
JP5656406B2 (ja) 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
US20070059785A1 (en) Biomarkers in cancer
US8956822B2 (en) Method for predicting the response to HER2-directed therapy
US20060094068A1 (en) Predictive markers in cancer therapy
CA2509543C (en) Method for predicting the response to her2-directed therapy
Hernández et al. PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study
Ames et al. Huntingtin-interacting protein 1: a Merkel cell carcinoma marker that interacts with c-Kit
EP2932273B1 (en) Inhibitors of soluble adenylyl cyclase for use in the treatment of prostate cancer
WO2011129427A1 (ja) 癌の診断剤および治療剤
US20210003574A1 (en) Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
JP5295268B2 (ja) がん疾患に罹患している患者の生物学的療法に対する感受性を測定するための方法
ES2527926T5 (es) HER3 activado como marcador para predecir la eficacia terapéutica
AU2013203603A1 (en) Activated HER3 as a marker for predicting therapeutic efficacy
US20150004605A1 (en) Biomarker and Uses Thereof
CN107828886A (zh) Gbp2基因和/或gbp2蛋白作为乳腺癌新的诊治靶点的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130410

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141125

R150 Certificate of patent or registration of utility model

Ref document number: 5656406

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250